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ABSTRACT 
 
In the European Union, amino acids, enzymes, pre- and probiotics, essential fatty acids, botanicals 
and botanical extracts and miscellaneous bioactive substances can be marketed as food 
supplements (FS). Food supplements that are meant to benefit human health contain claims on 
their label stating their benefits. Since 2007, health claims made on FS, are prohibited unless they 
are authorized and included in the EU Register of Nutrition and Health Claims on Food (the EU 
Register), in accordance with the requirements of Regulation (EC) nº 1924/2006. 
Aims: This manuscript reviews the evidence required to support health claims made on FS 
considering the legal framework of these foodstuffs and, as a case study, analyses the health 
claims on articular joint health included in the EU Register. The EFSA scientific opinions related to 
those health claims have also been considered. In EU, some botanicals and miscellaneous 
bioactive substances can be marketed as medicinal or as food supplements. The regulatory issues 
on botanicals and the debate on how to create a regulatory framework for botanicals is mentioned. 
Results: By April 2015, 77 functional health claims on joints health were included in the EU 
Register. The status of all these claims was non-authorised. The great majority were Article 13.1 
claims (91%). All functional claims related to articular joints function were made on target functional 
ingredients, mainly other substances that could be used in the manufacturing of FS. Human trials 
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conducted in diseased population were the main statement from EFSA for the non-approval of the 
health claims on articular joints. Criteria and more guidance addressing methodological issues on 
human trials would benefit future applications and scientific research.  
Conclusion: Legal issues regarding other substances than vitamins and minerals, namely 
botanical ingredients should also be taken in account in future FS health claims on articular joints. 
On this subject, efforts to improve the existing regulatory framework, namely with regard to 
botanicals products could also benefit future FS health claims. 
 
 
Keywords: Food supplements; health claims; health outcomes; EFSA; articular joint; rheumatoid 
arthritis. 
 
1. INTRODUCTION 
 
The political, socioeconomic and technological 
developments in Europe and other developed 
countries since the 1960’s made a more secure 
and abundant global food supply possible. This 
was an important factor in the increase in life 
expectancy. On the other hand, changes in diet, 
high stress levels and the prevalence of more 
sedentary lifestyles that are characteristic of 
developed societies had significant negative 
impacts in the health of the populations. In recent 
years the prevalence of chronic non-
communicable diseases (NCDs) has increased 
dramatically. In 2012, 38 million people died from 
NCDs [1]. Chronic diseases, such as obesity, 
diabetes mellitus and rheumatoid arthritis (RA), 
also cause high morbidity and disability, with 
serious social consequences and significant 
economic implications for the health of several 
countries systems [1,2]. Considering these facts 
a new paradigm, focused on the prevention of 
disease and in the promotion of people’s well-
being, is emerging [3,4,5].  
 
RA is a chronic systemic autoimmune disease, a 
multi articular syndrome of unknown cause, 
which is characterized by a persistent synovitis, 
synovial hyperplasia and inflammatory cell 
infiltration, presence of auto-antibodies and 
progressive destruction of cartilage and bone 
[6,7,8]. Studies made in European and North 
America countries estimate a prevalence RA 0.5-
1% and an average annual incidence of 0.02-
0.05% [9]. RA is associated with inflammation 
and progressive erosion of the joints leading 
often to loss of functionality, severe morbidity 
and premature mortality [10]. The deformations 
in synovial joints, especially small joints of the 
hands and wrists, symmetrically, lead to a limited 
range of motion. In the first year of disease onset 
about 70% of patients suffer irreversible joint 
destruction and approximately 80% of working 
age adults, experience disabling pain, stiffness 
and reduced functional capacity, with high costs 
for individuals and society [10]. In this context 
and given the global economic situation, 
research of anti-arthritic effects in food, food 
ingredients and / or extracts seems very 
interesting and important in terms of health 
outcomes.  
 
In the EU countries, plant preparations with 
pharmacological activity can be marketed as 
pharmaceutical products or as food supplements.  
Contemporary lifestyle issues, namely low 
nutrient density diet, lack of exercise and high 
levels of stress, created an opportunity for the 
food supplements market to growth. Food 
supplements are commonly used for health 
purposes and therefore are labelled with health 
claims indicating its benefits. In the EU market, 
the use of health claims made on food 
supplements is regulated under Regulation (EC) 
nº1924/2006, which imposes that only authorized 
claims, included in the EU Register, can be used 
in food.  
 
It is well established that plant preparations 
contain different biologically active compounds, 
many of them with a physiological effect in 
humans or even therapeutic [11]. The red 
raspberry (Rubus idaeus L.) fruit contains several 
nutrients (fiber, ascorbic acid and folates) and 
substances (bioactive phenolic compounds, 
mainly ellagitannins and anthocyanins) of 
pharmacological interest [12]. In a recent study, 
Figueira et al. [13] demonstrated the anti-
inflammatory effects of a red raspberry fruit 
extract rich in phenolic compounds, in a 
collagen-induced arthritis rat model. The authors 
suggested that red raspberry extracts with 
pharmaceutical activity could potentially be used 
as a dietary source of pharmacologically active 
compounds that may have an active role in 
delaying the progression of inflammatory articular 
injury associated with arthritic conditions.  
 
This article reviews the evidence required to 
support health claims made on food 
supplements, considering the legal framework of 
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this foodstuffs. The regulatory standpoint of 
health benefit for health joints is approached 
through an analysis of the Commission’s 
authorized and non authorized health claims 
made on foods and the published opinions of the 
Panel on Dietetic Products, Nutrition and 
Allergies (NDA) of the European Food Safety 
Authority (EFSA) on health claims applications. A 
special focus is given to health claims concerning 
articular joints. 
 
2. METHODOLOGY  
 
A literature search was conducted using online 
databases: Eur-Lex  
http://eur-lex.europa.eu/advanced-search 
form.html for the legal framework; EFSA 
(http://www.efsa.europa.eu/en/nda/ndaguidelines
.htm and 
http://www.efsa.europa.eu/en/nda/ndascdocs.ht
m, accessed April 2, 2015) for both guidelines on 
health claims and scientific opinions concerning 
health claims applications; the ‘EU Register of 
Nutrition and Health Claims’ 
(http://ec.europa.eu/nuhclaims/, accessed April 
2, 2015) for all the Commission’s authorized and 
non authorized health claim on foods related to 
joints. The Pubmed and B-on online databases 
were also used to retrieve publications 
considered in EFSA opinions for substantiation 
health claims concerning health benefits related 
to joints. Finally, health claims opinions published 
by EFSA regarding others health benefits were 
included for comparison purposes. 
 
3. RESULTS AND DISCUSSION 
 
3.1 Results  
 
3.1.1 Legal framework   
 
An overview of EU legislation relevant to food 
supplements and health claims on these 
products is summarized in Table 1.  
 
Food supplements are foodstuffs intended to 
supplement a normal diet. Food supplements 
(FS) are regulated in the UE under the Directive 
2002/46/EC (FSD) [14], implemented in Portugal 
into the Decreto-Lei nº 136/2003 of 28 July [15]. 
According to those acts, FS are concentrated 
sources of vitamins, minerals or other 
substances with a nutritional or physiological 
effect, taken alone or in combination, marketed in 
dose form (capsules, pastilles, tablets, pills, 
sachets of powder, ampoules of liquids, drop 
dispensing bottles, among others similar forms 
designed to be taken in measured small unit 
quantities). FSD and amended acts lays down a 
harmonised list of 30 vitamins and minerals 
(Annex I) that can be added for nutritional 
purposes in these foodstuffs and a list of 175 
permitted sources of vitamins and minerals 
(Annex II) from which FS can be manufactured.  
 
As foodstuff, all FS introduced in the EU market 
shall meet all requirements outlined in 
the General Food Law, in particular with regard 
to food safety [16]. Considering the food law 
definition and the food safety requirements set 
out in the Regulation (EC) nº 178/2002 (general 
food law), FS traded in EU market shall comply 
with the relevant laws, regulations and 
administrative provisions governing food safety, 
whether at Community or national level, including 
those relating to food information and nutrition 
(namely nutrition and health claims [17] and food 
for specific groups), food improvement agents 
(food additives, food enzymes and food 
flavourings), chemical safety (contaminants, 
residues, pesticides and extraction solvents), 
biological safety (including food hygiene and 
irradiation), novel food [18]. The Regulation (EC) 
nº 1925/2006 [19] regarding the food fortification 
contains a procedure (Articles 8) to cover 
situations where safety issues could arise with 
the addition of other substances to food 
supplements or used in the manufacture of such 
foodstuffs, namely botanical ingredients. 
However, the provisions of that Regulation 
regarding vitamins and minerals shall not apply 
to food supplements covered by FSD.  
 
Novel FS or FS containing novel ingredients (not 
present at a significant degree on the EU market 
before May 15, 1997) shall also meet the 
requirements of the Regulation (EC) nº 258/1997 
[20] concerning novel foods and novel food 
ingredients. According to that act, those novel FS 
or the novel ingredients, e.g. botanical 
ingredients used in its composition must be safe 
for the consumers and properly labelled to not 
mislead consumers. Unlike FS/ingredients 
presents at a significant degree on the EU 
market before May 15, 1997, marketing a novel 
FS or a novel ingredient requires prior 
authorisation as referred to in Regulation (EC) nº 
258/1997. Companies shall first apply to the EU 
National Authority, in which the product will be 
marketed, presenting the scientific information 
and safety assessment report.  
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Table 1. Overview of EU legislation relevant to food supplements and health claims 
 
Legislation Topic Relevance References 
Reg 178/2002 of the 
European Parliament and 
Council 
General food law 
 
General principles and 
requirements of food legislation 
and in matters of Food safety to 
be taken into account. Sets the 
procedures governing EFSA’s 
operation 
OJ L31, 1.2.2002, p.1 
 
Dir 2002/46 of the 
European Parliament and 
Council (as amended by 
Dir 2006/37, Reg 
1137/2008, Reg 
1170/2009,Reg 
1161/2011; Reg 
119/2014; Reg 2015/414) 
Food 
supplements 
 
Establishes specific rules for the 
labelling and on vitamins and 
minerals in food supplements 
 
OJ L183, 12.7.2002,p.51 
(OJ L94, 1.4.2006, p.32; 
OJ L311, 21.11.2008, 
p.1; OJ L314, 1.12.2009, 
p.36; OJ L296, 
15.11.2011, p.29; OJ 
L39, 8.2.2014, p.44; OJ 
L68, 13.3.2015, p.26) 
Reg 258/97 of the 
European Parliament and 
Council 
(under revision; as 
amended by Reg 
1829/2003, Reg 
1882/2003,  
Reg 1332/2008,Reg 
596/2009) 
Novel food/Novel 
food ingredients 
 
Establishes the rules for pre-
market authorisation procedure 
for new and innovative food 
(ingredients) which have  not 
been used for human 
consumption  to a significant 
degree within the EU before 15 
May 1997  
OJ L183, 12.7.2002,p.51 
(OJ L94, 1.4.2006, p.32; 
 
Reg 1924/2006 of the 
European Parliament and 
Council 
(as amended by Reg 
107/2008, Reg 109/2008, 
Reg 116/2010,Reg 
1169/2011, 
Reg1047/2012;  
Reg 907/2013) 
Nutrition and 
health claims on 
food 
 
Establishes the basic principles 
and requirements about Nutrition 
and health claims on food and 
food supplements; sets the 
authorisation procedure 
 
Corrigendum, OJ L12, 
18.1.2007,p.3 (OJ L39, 
13.2.2008, p.8; OJ L39, 
13.2.2008, p.14; OJ L37, 
10.2.2010, p.16; 
Corrigendum, OJ L247, 
13.9.2012,p.17; OJ L310, 
9.11.2012, p.36; OJ 251, 
21.9.2013, p. 7) 
Reg 1925/2006 of the 
European Parliament and 
Council 
(as amended by Reg 
108/2008) 
 
Addition of 
vitamins and 
minerals and of 
certain other 
substances to 
food 
 
Provisions of this Regulation 
regarding vitamins and minerals 
shall not apply to food 
supplements. However, this act 
contains a procedure to cover 
situations where safety issues 
could arise with the addition of 
other substances to food 
supplements or used in the 
manufacture of such foodstuffs, 
namely botanical ingredients  
OJ L404,30.12.2006, 
p.26 (OJ L39, 13.2.2008, 
p.8) 
 
Reg 353/2008 of the 
European Parliament and 
Council 
(as amended by Reg 
1169/2009) 
Health claims on 
food 
Establishes the basic law and 
requirements on nutrition and 
health claims on food, namely the 
authorisation procedure 
OJ L109,19.4.2008,p.11 
(OJ L314, 1.12.2009, 
p.34) 
 
Reg 764/2008 of the 
European Parliament and 
Council 
Free movement 
of food in the 
Internal Market 
Sets the procedures relating to 
the application of certain national 
technical rules to products 
lawfully marketed in another 
Member State 
OJ L218, 13.08.2008, 
p.21 
Reg 1169/2011 of the 
European Parliament and 
Council 
(as amended by Reg 
1155/2013,  
Reg 78/2014) 
Food information 
to consumers 
Establishes general Food 
information requirements, 
mandatory Food information, 
including nutrition declaration, 
distance selling, voluntary food 
information and requirements 
about national measures 
Corrigendum, OJ L247, 
13.9.2012,p.17 (OJ 
L306, 16.11.2013, p.7; 
OJ L27, 30.1.2014, p.7; 
OJ L37, 10.2.2010, p.) 
OJ – Official Journal; Reg – Regulation; Dir - Directive 
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The implementation of FSD with rules concerning 
certain aspects of vitamins and minerals has 
been an important key step to harmonise the 
regulation of FS across the EU. However, the 
use of substances with nutritional or 
physiological effects, other than vitamins and 
minerals, in FS is not yet harmonised. For these 
aspects national rules remain applicable and the 
national authorities shall apply the principle of 
mutual recognition to FS lawfully marketed in 
other EU member states (articles 34/36 of the EU 
Treaty) [21]. The Mutual Recognition Principle, 
as laid down in article 28 of the Treaty on the 
Functioning of the European Union (TFEU) 
relating to the prohibition of quantitative 
restrictions between Member States, is an 
important instrument for facilitating the free 
movement of those FS within the EU market [22, 
23]. According to this principle, unless it can be 
shown that there is a danger for human health, 
Member States are not allowed to prohibit, 
restrict or impose administrative procedures of 
equivalent effect, on imports of FS of another 
Member State if the FS is lawfully produced or 
marketed in the exporting Member State [23]. 
The Mutual Recognition Regulation (Regulation 
(CE) nº 764/2008), defines the rights and 
obligations of national competent authorities and 
those of enterprises wishing to sell in a Member 
State products lawfully marketed in another 
Member State, when the authorities intend to 
take restrictive measures regarding the product 
in accordance with their national technical rules 
[23,24]. This act, applicable since 13 May 2009, 
focuses in particular on the burden of proof by 
setting out the procedural requirements for 
denying mutual recognition [23,24].  
 
The FSD gives a broad definition of FS to include 
non-vitamin and mineral ingredients but does not 
specifies categories for those ingredients [14]. As 
there are no legal specifications regarding ‘other 
substances with a nutritional or physiological 
effect’ in the present work we will adopt the 
classification proposed by the European Advisory 
Services in a report for the European 
Commission, in 2007 [25]. According to the 
European Advisory Services ‘other substances 
with a nutritional or physiological effect’ are 
‘botanicals’ (herbs, plants, fungi, algae and 
extracts thereof) and ‘other bioactive substances’ 
[25]. This last term refers to any substance with a 
nutritional or physiological effect, other than 
vitamins, minerals and botanicals, namely amino 
acids, enzymes, pre- and probiotics, essential 
fatty acids and miscellaneous bioactive 
substances [25]. This classification was based: 
(i) on the substances other than vitamins and 
minerals found in the UE FS market; (ii) on well 
established biochemical classes of molecules; 
(iii) the nature and origin of the these substances 
[25]. Recently in this year EFSA NDA Panel.  
 
3.1.2 FS and health claims 
 
FS are generally designed to improve and/or 
maintain human health. Frequently, these 
foodstuffs contain claims on their label stating 
those benefits [26]. However, health claims on 
FS shall only be permitted if the nutrient or the 
substance in respect of which the claim has been 
made show to have a beneficial physiological 
effect [17]. The Regulation (UE) nº 1924/2006 
distinguishes two categories of claims: nutrition 
claims (Article 8) and health claims (Articles 13 
and 14). According the Regulation (EC) nº 
1924/2006 [17], health claims on FS are 
statements that imply that a relationship exist 
between a FS category, a FS or one of its 
constituents and a health condition [17,26]. 
There are four types of health claims (Fig. 1): 
functional claims, generic or based on new 
evidence, with or without proprietary data 
protection (Article 13.1 and Article 13.5, 
respectively) or claims regarding disease risk 
reduction (Article 14.1.a) or children development 
or health (Article 14.1.b) [17]. General function 
claims deals mainly with claims describing or 
referring to ‘the role of a nutrient or other 
substance in growth, development and functions 
of the body; or psychological and behavioural 
functions; or, without prejudice to Regulation 
(EU) nº 609/2013 [27], slimming or weight-control 
or a reduction in the sense of hunger or an 
increase in the sense of satiety or to the 
reduction of the available energy from the diet’. 
Those claims have been submitted until January 
2008, through the competent authorities of 
different Member States. New function claims are 
‘based on newly developed scientific evidence 
and/or which include a request for the protection 
of proprietary data’. Finally, reduction of risk 
claims are health claims that ‘states, suggests or 
implies that the consumption of a food category, 
a food or one of its constituents significantly 
reduces a risk factor in the development of a 
human disease’. In EU, claims for the prevention, 
treatment or cure of human disease (medical 
claims) are reserved for medical products [28]. 
 
Unlike general functional claims that are based 
on ‘generally accepted scientific evidence’, 
Article 13.5 and Article 14 health claims require 
prior authorisation and a submission of an 
extensive dossier with the scientific data (see 
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Table 2 for an overview of key requirements for 
these health claims on food supplements). The 
implementing rules for applications for 
authorisation of health claims as provided for in 
Article 15 of Regulation (EC) nº 1924/2006 has 
been established in the Regulation (EC) nº 
315/2008 [29]. The dossier provided by the 
applicant shall demonstrate that [29]: the claimed 
effect of the FS is ‘beneficial for human health’; ‘a 
cause and effect relationship is established’ 
between consumption of the FS and the claimed 
effect in humans (such as the strength, 
consistency, specificity, dose-response, and 
biological plausibility of the relationship); the 
quantity of the FS and ‘pattern of consumption 
required to obtain the claimed effect could 
reasonably be achieved as part of a balanced 
diet’; ‘the specific study group(s) in which the 
evidence was obtained is representative of the 
target population for which the claim is intended’. 
 
According to Regulation (EC) nº 353/2008 [29], 
the applicant must provide all the available data 
(including data published and unpublished, in 
favour and not in favour) that are pertinent to the 
proposed health claim, together with a 
comprehensive review of the data from human 
studies, demonstrating that the heath claim is 
substantiated, in a stand-alone dossier. Each 
application must cover only one relationship 
between a FS or constituent (nutrient or other 
substance), and a single claimed effect. Scientific 
data in the dossier shall consist primarily of 
studies in humans (human intervention and 
observational studies and other human studies 
dealing with the mechanisms by which the FS 
could be responsible for the claimed effect, 
namely studies on bioavailability) followed by 
non-human data, animal data and ex vivo or in 
vivo data (e.g. mechanistic studies), when 
appropriate. Randomized controlled human 
studies (RCT) are, among the human 
intervention studies those that can generate the 
strongest scientific evidence.  
 
EFSA (particularly NDA Panel) assesses the 
scientific substantiation of all applications for 
health claims from EU Member States [17]. 
Under this work EFSA NDA Panel has conducted 
several consultations and published scientific 
advice and technical guidance to assist 
applicants in the preparation of applications for 
the authorisations of health claims [30]: general 
guidance on how to submit claims [31,32] and 
specific guidance on scientific requirements for 
health claims related to some beneficial 
physiological health effects to human health (see 
Table 3 for an overview of EFSA’s relevant 
guidance for FS health claims on joints). In 
general terms, the criteria used by the EFSA 
NDA Panel for the assessment procedure of 
health claims have been the following [32]: (i) the 
food/food supplement or food ingredient is 
defined and characterized; (ii) the claimed effect 
is defined and the claimed effect is a beneficial 
physiological effect; (iii) A cause and effect 
relationship is established between the 
consumption of the food/food supplement or food 
ingredient and the claimed effect. Generally, a 
favourable outcome on all those three criteria 
leads to a positive opinion on the claim [32].  
When that is verified, EFSA NDA Panel further 
evaluates the following aspects of the claims 
[32]: (a) the effect on the function is significant in 
relation to the quantity of the food proposed to be 
consumed and if this quantity could reasonably 
be consumed within a balanced diet; (b) the 
suggested wording reflects the scientific 
evidence; (c) the suggested wording and the 
proposed conditions and restrictions of use 
comply with the specific conditions set out in 
Article 10 of the Regulation (EC) nº 1924/2006.  
 
HEALTH CLAIMS 
FUNCTION CLAIMS CLAIMS REGARDING 
General Function 
Claims 
(Article 13.1) 
 
Based on Generaly 
Accepted Scientific 
Evidence including 
Scientific Studies 
In Humans 
New Function 
Claims 
(Article 13.5) 
 
Based on New 
Scientific Evidence or 
Protection of 
Propriety Data 
including  
Scientific Studies 
In Humans 
 
Disease Risk 
Reduction 
(Article 14.1.a) 
 
Based on Specific 
Scientific Studies 
In Humans 
Child Development or 
Health 
(Article 14.1.b) 
 
Based on Specific 
Scientific Studies 
In Children 
 
Fig. 1. Schematic overview of health claim types in the Regulation (CE) Nº 1924/2006 
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All NDA Panel scientific assessment are 
published in the EFSA Journal as EFSA scientific 
opinions.  
 
In practice, the possible conclusions of each 
EFSA claim assessment outcome are the 
following [32]: (I) a cause and effect relationship 
has not been established between the 
consumption of the food/food supplement or food 
ingredient and the claimed effect (e.g. where the 
scientific evidence is limited and is not supported 
by the so-called ‘generally accepted scientific 
evidence’); (II) the evidence provided is 
insufficient to establish a cause and effect 
relationship between the consumption of the 
food/food supplement or food ingredient and the 
claimed effect (e.g. where the scientific evidence 
is limited and is not supported by the so-called 
‘generally accepted scientific evidence’); (III) a 
cause and effect relationship has been 
established between the consumption of the 
food/food supplement or food ingredient and the 
claimed effect. These scientific opinions are used 
by the Commission to decide on the approval 
and market access or on the rejection of the 
claims. Finally, the outcome of the Commission´s 
decision is published as a Commission 
Regulation and all claims are included in an 
online database of permitted and non-authorised 
health claims, the EU Register of Nutrition and 
Health Claims made on Foods, hereinafter 
referred to as ‘the EU Register’, including FS 
(http://ec.europa.eu/nuhclaims/) [18]. 
 
3.1.3 Health claims for articular joint health  
 
By April 2, 2015 Commission had reviewed and 
decided on 2282 health claims: 11 % were 
authorized while the great majority was non-
authorized (89%). General claims (92%) were 
the predominant types of claims listed in the EU 
Register; new function claims and claims
 
Table 2. Implementation of EU regulation Nº 1924/2006: overview of key requirements for 
health claims on food supplements 
 
Legal Requirement (reference in the act) Health Claim Type 
NF 
(Article 13.5) 
DRR 
(Article 14.1.a) 
CDH 
(Article 14.1.b) 
REG 1924/2006* 
The health claim shall comply /be … 
I. With the General Conditions, namely:  
   
… truthful, clear, reliable (Article3), useful (Article 5.2) and their 
use justified (Article 6.2) by all relevant elements and data 
(Article 6.3); 
√ 
 
√ 
 
√ 
  
 
In the Food Supplements, the nutrient(s) or substance(s) 
for which the claim is made is in a quantity that will 
produce the physiological effect claimed and is in a form 
that is available to the body(Article 5.1); 
√ 
 
√ 
 
√ 
 
II. With the Specific Conditions, namely:    
… authorized for use after a scientific assessment by 
EFSA(Article 10); 
√ 
 
√ 
 
√ 
 
… undergoing an accelerated authorisation 
procedure(Article 18); 
√ X X 
… undergoing an complex authorisation procedure(Articles 
15-17, 19); 
X √ √ 
REG 353/2008*    
III. An applicant for a health claim authorisation shall 
comply  /be … 
   
… prepared and presented complying with the technical 
rules established in the Annex(Article 10; ); 
√ √ √ 
… to newly generally scientific evidence(Article 1.b, 4); 
… to protection of  proprietary data when requested(Article 
1.b, 4); 
√ 
 
√ 
X 
 
√ 
X 
 
√ 
…requiring a complete dossier containing all relevant 
scientific data(Article 1.a); 
√ √ √ 
 
… referring primarily to data from human studies(Article 5); √ √ √ 
…referring primarily to data from scientific studies in 
children(Article 5); 
X X √ 
* - and Amended Acts; √ - applicable; X – not applicable; NF – new function claims; DRR – disease risk reduction claims; CDH 
– children development or health 
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regarding disease risk reduction claims and child 
development or health were in great minority 
(4%, 2% and 2%, respectively). It is important to 
note that scientific assessment of Article 13.1 
claims did not require the submission of dossiers 
by applicants [17]. EFSA received from the 
Member States via European Commission a list 
of those claims ‘accompanied by the conditions 
applying to them and by references to the 
relevant scientific justification’ [17]. 
 
Among the 2282 health claims 77 and 66 (3.1% 
and 2.9%) contained, respectively the descriptors 
‘joint’ and ‘maintenance of joint’ and 44 of these 
claims relates to a health relationship on 
‘maintenance of joint’ (Table 4). The FS 
constituents that were the subject of the 77 
health claims on joints health, grouped into the 
four categories proposed by the European 
Advisory Services [25] are presented on Table 5. 
  
Table 3. Overview of EFSA’s relevant guidance for FS health claims on joints 
 
Document Topic Relevance  Reference 
EFSA NDA Panel Scientific 
Opinion Scientific and 
technical guidance for the 
preparation and presentation 
of an application for 
authorisation of a health claim 
(revision 1). 
General Guidance on 
how to submit claims 
 
 
 
 
Covers the general require-
ments for the preparation and 
presentation of an application 
for authorisation of a health 
claim. 
 
 
EFSA Journal  
2011;9(4):2170  
 
 
 
 
 
EFSA NDA Panel Scientific 
Opinion General guidance for 
stakeholders on the evaluation 
of Article 13.1, 13.5 and 14 
health claims. 
General Guidance on 
how to submit claims 
Covers the principles applied by 
the EFSA NDA Panel in the 
evaluation of health claims. 
EFSA Journal 
2011;9(4):2135 
EFSA NDA Panel Scientific 
Opinion Guidance on the 
scientific requirements for 
health claims related to bone, 
joints, skin, and oral health 
 
Specific Guidance on 
the scientific 
requirements for health 
claims related to joints 
Sets guidelines on the scientific 
requirements for health claims 
related to joints health, 
representing the views of the 
NDA Panel based on the 
experience gained to March 
2011 with the evaluation of 
joints health claims. 
EFSA Journal  
2009; 7(9):280 
 
ESCO Report. Advice on the 
EFSA guidance document for 
the safety assessment of 
botanicals and botanical 
preparations intended for use 
as food supplements, based 
on real case studies 
Safety Assessment of 
botanicals and 
botanicals preparations 
intended for use as 
ingredients in food and 
food supplements 
This guidance document 
focuses on the safety 
assessment of botanicals and 
botanicals preparations 
intended for use as ingredients 
in food and food supplements, 
including the safety assessment 
of botanicals reported to contain 
toxic, addictive or psychotropic 
substances and of botanicals 
reported to have also a 
medicinal use. 
EFSA Journal 
2009; 7(9):280 
EFSA – European Food Safety Authority; ESCO - EFSA Scientific Cooperation; EFSA NDA Panel – EFSA Scientific Panel on 
Dietetic Products, Nutrition and Allergies; FS - Food Supplements. 
 
Table 4. Health Claims on Joints included in the EU Register on Nutrition and Health Claims* 
 
 General function claims 
(Article 13.1) (nº) 
“New” function claims 
(Article 13.5) (nº) 
Disease risk reduction claims 
(Article 14.1.a) (nº) 
Search term   Permitted Non-authorised Permitted Non-authorised Permitted Non-authorised 
Joints 
Maintenance 
of Joint 
0 
0 
70 
64 
0 
0 
7 
2 
0 
0 
0 
0 
Maintenance 
of Joint** 
0 43 0 1 0 0 
* Accessed on April 2, 2015 (http://ec.europa.eu/nuhclaims/?event=search); ** - √ Match the entire phrase 
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Table 5. FS and FS ingredients target regarding Health Claims on Joints included in the EU 
Register on Nutrition and Health Claims* 
 
                    FS or FS Constituent 
Nutrient/Other substances    HC (nº)  
Minerals 10 
 
Boron, Zinc, Selenium, Silica 
Botanicals 7 Astaxanthin from Haematococcus pluvialis, Advocado-soy 
extract, Citrus flavonoid extract, Cherries (Prunnus Cerasus L.) 
extract, Pineapple (Ananas comosus L.) stem  
Essential fatty acids 19 EPA/DHA, Evening Primerose oil (Oenothe Biennis (L.)), 
Borage oil (Borage officinalis L.), Fish oil, Gamma – linolenic 
acid, Krill oil extract 
Miscellaneous bioactive 
substances 
41 Soy Isoflavones, Shark cartilage extract, Chondroitin sulphate, 
Glucosamine, Hyaluronic acid, Mucopolysaccharides, SAMe, 
Collagen hydrolysate, Monométhylsilanetriol, 
Methylsulfonylmethan (MSM), Green Lipped Mussel (Mussel 
perna canaliculus), Keratine powder extract, jelly royal, Sulphur 
Total 77  
* Accessed on April 2, 2015 (http://ec.europa.eu/nuhclaims/?event=search); HC- Health claims; EPA - Eicosapentaenoic acid; 
DHA - Docosahexaenoic acid 
 
The nutrient or substance target that were the 
subject of all 77 health claims on joints health 
included minerals (13%) and above all other 
substances (87%) (Table 5). Among other 
substances that could be used in FS there were 
primarily miscellaneous bioactive substances 
(53%), essential fatty acids (e.g. the omega-3 
fatty acids, eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) (25%) and some 
botanicals extracts (9%). The miscellaneous 
bioactive substance category reunited various 
substances, namely glucosamine, chondroitin 
sulphate, hyaluronic acid and soy isoflavones, 
some extracts of animal origin (e.g. shark 
cartilage extract and keratine powder extract) 
and even an honey product (jelly royal), not to 
constitute a new category with this ingredient. 
 
As noted above, all these function claims were 
considered non-authorised. They were mainly 
general functional claims (91%). In the EU 
Register, the reasons shown for the non-
authorization of the health claims related to joints 
are the following: ‘Non-compliance with the 
Regulation because on the basis of the scientific 
evidence assessed, this claimed effect for this 
food has not been substantiated’ (69 Article 13.1 
claims and 6 Article 13.5 applications) ‘Non-
compliance with the Regulation because on the 
basis of the scientific evidence assessed, this 
claimed effect for this food is not a beneficial 
physiological effect as required by the 
Regulation.’ (1 Article 13.1 claim); ‘this claimed 
effect attributes to this food the property of 
preventing, treating or curing a human disease, 
or refers to such properties which is prohibited 
for foods. Non-compliance with the Regulation 
because on the basis of the scientific evidence 
assessed’ (1 Article 13.5 application). Briefly, 
these statements include one medical claim, one 
claimed effect not considered a beneficial 
physiological effect, while for the great majority 
(97%) the claimed effect has not been 
scientifically substantiated. A deeper 
understanding of the reasons for these rejections 
requires an analysis of the scientific opinions 
from EFSA.  
 
In the EFSA Scientific Opinions related to 
maintenance of joint health, the NDA Panel 
concluded that a cause and effect relationship 
has not established between the consumption of 
the nutrients or substances and the maintenance 
of normal joint. Globally, the main statements 
that EFSA Panel considered for the non-approval 
of the health claims on joints are the following: 
the human studies conducted in diseased 
population (namely RA [33], osteoarthritis [34] 
and juvenile arthritis [35]; the results from studies 
in diseased population cannot be extrapolated to 
the maintenance of a joint’s function in the 
general population; studies with outcomes 
unrelated to the claimed effects [36]). According 
to the NDA Panel, a diseased population is not 
representative of the general population with 
regard to the functional conditions of the joints 
[34,35]. Some of the intervention studies were of 
small sample sizes and did not include healthy 
controls [37]. A number of references were 
provided on studies performed in animals and in 
vitro [34]. On this type of evidence, namely in a 
scientific opinion related to citrus bioflavonoids 
and maintenance of joint [34] the NDA Panel 
considered that the evidence provided in animal 
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studies and/or in vitro studies was not sufficient 
to predict the occurrence of an effect of the 
food/food constituent and the maintenance of 
normal joints in vivo in humans.  Some of the 
studies provided for joints health claims have 
been carried out with the target substance for 
which the claim was made mixed with others 
ingredients or with others substances [38]. The 
NDA Panel did not considered those studies as 
pertinent, i.e. studies from which conclusions can 
be drawn for the scientific substantiation of the 
claim [39]. Finally, in a randomized double-blind 
placebo controlled trial provided in the 
application referred above, the NDA Panel 
pointed out some negative aspects related to the 
statistical analysis (power calculation, missing 
data and multiple comparisons adjustment) [38]. 
As result, that evidence has been considered 
irrelevant for the scientific substantiation of the 
claim. On the other side, the NDA Panel stated 
clearly that claimed effects like ‘joint health’ 
[37,40], ‘joint support’ [41], ’joint mobility’ [42], 
among others, relate to the maintenance of 
normal joints. In all cases, EFSA recognizes that 
maintenance of normal joints is beneficial to 
human health, assuming that the target 
population is the general (healthy) population. An 
overview of some of the 21 Scientific Opinions of 
the NDA Panel relating to the 77 submitted 
applications for health claims on maintenance of 
joint health is presented in Table 6.  
 
The health claim related to EffEXTTM, a lipid 
standardized extract from the crustacean 
Euphausia superba (Antarctic Krill), and the 
claimed effect ‘helps to support joint function by 
maintaining low levels of plasma C-reactive 
protein’ was considered by the NDA Panel to be 
a medicinal claim [43] (Table 6.). This claim 
refers to a reduction of inflammation indicated by 
a lowered concentration of plasma C-reactive 
protein. According to NDA Panel, ‘whether or not 
reduction of inflammatory markers is considered 
beneficial depends on the context in which a 
claim is made’ [43]. Although the target 
population was adults presenting with sensitive 
joints, the randomized, double bind, placebo 
controlled study that supported the scientific 
assessment of the claim was carried out in 
patients with confirmed inflammatory diseases, 
namely osteoarthritis and rheumatoid arthritis 
[44]. In that context, the NDA panel concluded 
that the reduction of inflammation in the context 
of that diseases is a therapeutic target for the 
treatment of the disease and does not comply 
with the criteria laid down in Regulation (EC) No 
1924/2006 [43]. Finally, the health claim 
regarding a bee product, Royal jelly, and an anti-
inflammatory effect (helps to reduce inflammation 
in joints and muscles’) based on changes in 
markers of inflammation (various interleukins) 
was evaluated by the NDA Panel [45]. As no 
evidence has been provided in which context the 
claimed effect could be considered as a 
beneficial physiological effect, the Panel 
concluded that for this case, the reduction of 
inflammation was not considered a beneficial 
physiological effect as required by the Regulation 
[45]. 
 
Although all health claims applications on 
articular joints were refused authorisation, one 
general function claim on vitamin C related to 
cartilage formation was authorised - ‘Vitamin C 
contributes to normal collagen formation for the 
normal function of cartilage [46]. As cartilage 
formation is related to joints this health claim and 
their EFSA positive opinion will also be 
considered in the following discussion. Bioactive 
phenolic compounds from red raspberry, above 
all ellagitannins and anthocyanins, are 
substances with potential value regarding the 
joints health [13,47]. Even though scientific 
evidence on a possible beneficial physiological 
effect of those phytochemicals on joints is still 
very insufficient, the discussion will also consider 
a favourable assessment of EFSA on olive oil 
polyphenols.  
 
3.2 Discussion 
 
In Europe, the prevalence of joint disease, 
including RA, is high but there is a considerable 
proportion of subjects in the general population 
who complain of joint pain or joint discomfort, 
even without evidence of disease [9,48]. While 
the treatment of joint diseases must be 
addressed by pharmacological treatments, 
among others, such complaints could improve 
with the intake of FS which claim an effect on 
joints health. According to Bruyère et al. [49], a 
substantial proportion of subjects with joint 
discomfort or at risk of joint disorder use FS 
claiming a beneficial effect on joint and cartilage 
health. The analysed health claims on joints are 
related to ingredients (a nutrient or other(s) 
substance(s)) that can be used in FS.  
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Table 6. Overview of some EFSA NDA panel scientific opinions regarding heath claims on 
joints 
 
EFSA 
Opinion  
Reference 
Nutrient or 
Substance 
Claim(ID Entry) Status Assessment 
Statement 
EFSA Journal 
2009:7(9): 
1229 
 
Zinc 
 
 
 
Zinc promotes joint health Zinc helps 
support the function of the joints (ID 305). 
NA The claimed effect has 
not been substantiated. 
Criterion III was not 
observed. 
EFSA Journal 
2009:7(9): 
1261 
 
Boron  
as Boric Acid 
Boron helps build and maintain healthy 
joints. Boron helps maintain the 
flexibility and mobility of the joints (ID 
219); Boron may help maintain joint and 
bone health. Boron involved in joint 
health. Boron required for joint health 
(ID 220)
. 
NA The claimed effect has 
not been substantiated. 
Criterion III was not 
observed. 
EFSA Journal 
2009:7(9): 
1266 
 
 
Hyaluronic Acid The Hyaluronic Acid in SchiffÂ® Move 
FreeÂ® helps lubricate and support 
joints (ID 1572); Helps keep mobility of 
joints. Helps to keep healthy joints (ID 
3132)
. 
NA 
 
 
 
The claimed effect has 
not been substantiated. 
Criterion III was not 
observed. 
EFSA Journal 
2009:7(9): 
1477 
Gamma-Linolenic 
Acid provided by 
evening primrose 
oil and/or borage 
(starflower) oil 
Helps maintain healthy supple and 
flexible, mobile joints (ID 494); Helps 
maintain joint health/ supports joint 
flexibility/supports mobility (ID 637); 
Helps maintain joint health/supports 
joint flexibility/supports mobility (ID 1744). 
 
NA 
The claimed effect has 
not been substantiated. 
Criterion III was not 
observed. 
EFSA Journal 
2010:8(2): 
1477 
Gamma Linolenic 
Acid; Oenothera 
biennis (Common 
Name : Evening 
Primrose) 
Improves mobility and elasticity of 
joints. Activates absorption of calcium 
in intestinal tract thus increasing bone 
tissue density (ID 1774); Helps maintain 
supple and flexible joints (ID 2098). 
NA The claimed effect has 
not been substantiated. 
Criterion III was not 
observed. 
EFSA Journal 
2009:7(9): 
1493 
Mucopolysacchar
ides; Isoflavones 
Mucopolysaccharides help maintaining 
healthy joints (ID 3624); helps to maintain 
mobility of joint during and after 
climacterium (ID 3144); 
NA The claimed effect has 
not been substantiated. 
Criterion III was not 
observed. 
EFSA Journal 
2010:8(2): 
1477 
Gamma  
Linolenic Acid 
Improves mobility and elasticity of 
joints. Activates absorption of calcium 
in intestinal tract thus increasing bone 
tissue density (ID 1744); 
 
NA 
The claimed effect has 
not been substantiated. 
Criterion III was not 
observed. 
EFSA Journal 
2010;8(2): 
1493 
Citrus 
bioflavonoids 
Citrus bioflavonoids may help to keep 
joints healthy. (ID 1799); 
NA The claimed effect has 
not been substantiated. 
Criterion III was not 
observed. 
EFSA 
Q-2012-00386 
 
 
EffEXT™* EffEXT™ may help to support joint 
function by maintaining low levels of 
plasma C-reactive protein; 
NA The claimed effect 
attributed to this food is 
the property of 
preventing, treating or 
curing a human 
disease, or refers to 
such properties that are 
prohibited for foods.  
Criterion III was not 
observed. 
EFSA Journal 
2010;8(10): 
1799 
Gelée Royale** Gelée Royale may help to reduce 
inflammation in joints and muscles. (ID 
1327); 
NA The claimed effecf for 
this food is not a 
beneficial physiological 
effect as required by 
the Regulation. 
Criterion II was not 
observed. 
NA – Not Approved; * Article 13.5; **Royal Jelly; TO DEFINE “CRITERION III”, “Criterion II” 
  
 
 
Bettencourt-Câmara et al.; EJNFS, 6(1): 12-35, 2016; Article no.EJNFS.2016.003 
 
 
 
23 
 
All 77 functional health claims on joints health 
submitted under the Regulation (EC) nº 
1924/2006 on nutrition and health claims on food 
were refused authorisation. Indeed, 76 of the 
proposed health claims on joints were 
considered not supported by a sufficient body of 
scientific evidence able to substantiate the 
relationship between the consumption of the 
foodstuff and the claimed effect. The EFSA NDA 
Panel stated that results from studies performed 
in diseased population subgroups cannot be 
used for the scientific substantiation of health 
claims on joints function in the general population 
[39]. It is important to note that EFSA’s specific 
guidance on the scientific requirements for health 
claims related to joints became available in 2011 
(the draft version) for public consultation. The 
final version of that guidance was published in 
2012. This EFSA document aims to assist 
applicants in preparing and submitting their 
applications for the authorization of health claims 
on joints. However, the vast majority of the 
applicants of the health claim applications on 
joints analysed (70 general functional health 
claims), if not all applicants (70 Article 13.1 
claims and 7 Article 13.5 claims) did not 
benefited from such guidance. On the contrary, 
the NDA Panel set out its guidance in the area of 
joints health from the evaluation of the vast 
majority of those applications [39]. 
 
On the subject of applications about food / 
foodstuff / substances or nutrients claiming 
treatment or prevention of joint diseases, Article 
7.3 of Regulation (EU) nº 1169/2011 on the 
provision of food information to consumers [8] 
clearly states that ‘Subject to derogations 
provided for by Union law applicable to natural 
mineral waters and foods for particular nutritional 
uses, food information shall not attribute to any 
food the property of preventing, treating or curing 
a human disease, nor refer to such properties’. 
The law prohibiting ‘the use of information that 
would mislead the purchaser or attribute 
medicinal proprieties to food’ [17] was also 
explicit in the general labelling EU provisions, the 
Directive 2000/13/EC on food labelling, repealed 
in 2011 by the act mentioned above. This legal 
requirement is also part of the legislation on FS, 
in particular Article 6.2 of the FSD.  
 
Comparing all statements found in the EFSA 
reports evaluating the 77 health claim relating to 
joints health it is important to emphasize that in 
all cases, the target nutrients/substances are 
sufficiently characterized. Success in meeting the 
first criterion used by EFSA in the evaluation of 
health claims can be attributed to the ingredients 
found in these applications. In most cases (87%), 
those ingredients are 'other substances'. 
Generally, the constituents claiming the 
physiological beneficial effect on joints function 
are well defined and characterized and can be 
measured in foodstuff by established methods. It 
is important to emphasize that in those cases, as 
with drugs, only one or a limited number of active 
components were measured. These results raise 
the following question: Would more complex 
matrices such as food in general or even the red 
raspberry extract rich in phenolic compounds 
[13], mentioned above be positively evaluated by 
EFSA with regard to this criterion or, as olive oil 
polyphenols (e.g. hydroxytyrosol and oleuropein 
complex) that have been positively assessed by 
EFSA [50] should the focus be placed on only 
some of its bioactive phenolic compounds? It is 
important to clarify that the olive oil constituents 
subject of the health claim regarding olive oil are 
olive oil polyphenols standardized extracts, 
namely a hydroxytyrosol or oleuropein complex 
and an Olea europaea L. extract standardized to 
4-23% oleuropein. Those phenolic acids can be 
found in the olive fruit, olive mill waste waters or 
olive oil, Olea europaea L. extract and leaf [50]. 
 
The preparation of a stand-alone dossier 
containing the information and the scientific data 
submitted for authorisation of a health claim 
related to the consumption of a FS or its 
constituents, including other substance or 
substances, requires compliance with certain 
legal requirements particularly with regard to 
food safety issues. The legal framework 
regarding these products has some limitations 
that are worth discussing. 
 
At the European level, the FSD [14] harmonises 
partially the legal framework for the manufacture 
and marketing  of products containing vitamins 
and minerals, laying down a European-wide 
positive list of vitamins and minerals that can be 
used in FS and their specific forms. The key 
provisions of the FSD include also specific 
labelling provisions. Decreto-lei nº 136/2003 of 
July 28 [15], implements that legislation in 
Portugal. FS may be, according to the explicit 
definition found in these acts, concentrated 
sources of other substances with a nutritional or 
physiological effect taken alone or in 
combination, marketed in dose form. However, 
‘other substances’ are not defined or included in 
those acts although it is generally understood 
that these substances could include, but not limit 
to, amino acids, enzymes, pre- and probiotics, 
essential fatty acids, fibers and various 
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botanicals and botanical extracts like the           
Rubus idaeus L. extract referred previously. The 
term ‘nutritional and physiological effect’ is also 
not defined in Directive 2002/46/EC or in 
Decreto-lei nº 136/2003 of July 28 and neither 
does it clarify the botanicals species and 
varieties that can be used in the manufacture of 
FS. (EU) nº 1924/2006 defines ‘other 
substances’ as substances other than vitamins or 
minerals that have a nutritional or physiological 
effect however, the term ‘nutritional and 
physiological effect’ is not clarified [17]. It is 
interesting to highlight that the Croatian 
regulation on substances that may be added to 
foods and use in food and substances whose 
use in foods is prohibited or restricted, considers 
other substances as amino acids, essential fatty 
acids, fiber, plant organs, plant extracts, herbal 
products, microorganisms, edible fungi, algae, 
bee products and other substances with 
nutritious or physiological effect [51]. A recently 
subject to public consultation EFSA NDA Panel 
draft general guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health 
claims published in March 2011 defines other 
substances as ‘any food/ constituent which is not 
an essential nutrient’ [52]. This document 
establishes also that the  general applied by the 
NDA Panel for the assessment of health claims 
on other substances differ from those applied for 
the assessment of claims functions of essential 
nutrients. The differences refer to the 
requirements for the definition of the claimed 
effect, for the scientific substantiation of the 
claim, and for establishing conditions of use [52]. 
Once it is adopted, this NDA Panel document will 
supersede the general guidance for stakeholders 
on the evaluation of Article 13.1, 13.5 and 14 
health claims and the pre-submission guidance 
on administrative and procedural questions for 
applicants intending to submit applications for 
authorisation of health claims made on foods 
[52]. 
 
Permitted botanicals used, as target substances 
for the purpose of health claims, must assure 
their safety. In this regard it is important to note 
that the European Commission put those Article 
13.1 claims on hold [52]. Also, FS not present at 
a significant degree on the EU market before 
May 15, 1997 should be previously authorized as 
new ingredients, as e.g. Krill oil, the functional 
ingredient of health claims related to the 
improvement of joint flexibility, the maintenance 
of joint comfort and the maintenance of joint 
mobility [53,54].  
 
Considering the aforementioned, in the case of 
other substances with a physiological effect, 
namely botanicals, the EU legislation ensures 
limited harmonization. As a consequence, there 
are major differences among the rules for 
marketing FS in the different EU member States 
(Table 7). Therefore, decisions regarding the 
safety and effectiveness of FS with those 
ingredients depend mainly on national legislation 
and manufacturer’s practices [11]. Portuguese 
legislation, establish rules regarding vitamins and 
minerals that can be used in the manufacture of 
FS but nothing is explicit regarding other 
substances. A provision intended to facilitate 
efficient monitoring of FS (Article 9 of Decreto-Lei 
nº 136/2003), requiring the manufacturer or the 
person placing the product on the market to 
notify the competent authority of that action by 
forwarding to the authority a copy of the label 
used for the product. This notification can assure 
some control over the other substances used in 
FS. Generally, in Portugal a various range of 
other substances are permitted for use in FS 
either under national law or internal guidelines 
Regulation (Table 7). On the contrary, e.g. in 
France, those ingredients are not currently 
permitted, although its use in FS may be 
permitted following a pre-marketing 
authorisation. 
 
The main categories of other substances within 
the EU market are amino acids, enzymes, pre- 
and probiotics, essential fatty acids, botanicals 
and botanical extracts, and miscellaneous 
bioactive substances [24]. Specific rules for the 
use of other substances are subject to national 
law and/or internal guidelines, with negative and 
positive lists and considering specific conditions 
of use. A significant proportion of the EU market 
of the miscellaneous bioactive substances and 
botanicals (e.g. glucosamine, gingko) is 
composed of products registered as medicines 
(e.g. glucosamine is considered by the German 
authorities to be a medicine whereas in others 
Members States, namely UK, is available as FS) 
[22]. These borderline cases regarding 
botanicals and other bioactive substances, 
namely herbal extracts, are used in FS and for 
manufacturing proprietary medicinal products, in 
particular traditional herbal medicinal products 
[23]. Medicinal products are regulated under the 
Directive 2001/83/CE, the Directive 1999/83 for 
medicinal products with well-established use, 
and under the Directive 2004/24/CE on 
Traditional Herbal Medicine Products adopted in 
2004 [55,56,57]. In some UE Member States 
some botanicals products and miscellaneous 
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bioactive substances are regulated under the 
Traditional Herbal Medicine Products Directive 
(THMPD), through a simplified traditional use 
registration that recognizes, under certain strict 
conditions, the importance of the evidence of 
‘traditional use’ regarding the safety and the 
efficacy of those products (30 years of traditional 
use in Europe or 15 years in Europe and 15 
years in the world; a prove of efficacy is not 
required) [57]. This approach and the one 
established by Regulation (CE) Nº 1924/2006 
regarding claims on food and foodstuff are, as 
we shall see below, contradictory. 
 
The second criterion adopted by EFSA for the 
scientific assessment of health claims on 
foodstuff - the claimed effect is defined and is 
beneficial – has been verified successfully in the 
vast majority of the 77claims. It is important to 
note that for function claims, the ‘maintenance of 
joint function’ claimed by 86% of the applications 
for joints analysed, viewed by the NDA Panel as 
a possible ‘reduced loss’ of joint function [36], is 
considered a beneficial physiological effect. For 
these claims, a beneficial effect can also relate to 
the improvement of joint function. Considering 
the analysis in the broader perspective of the 
2822 claims evaluated up to April 2, we find that 
in many cases the NDA Panel did not consider 
the effect claimed in applications as beneficial to 
human health, such as in claims related to 
antioxidants [4,58] and probiotics [59,60].  
 
The implementation of Regulation (EC) No 
1924/2006, particularly the scientific assessment 
of the health claims applications, has been 
controversial. EFSA assesses the substantiation 
of health claims based on scientific evidence of 
the highest possible standard and the European 
Commission and Member States decide on their 
authorisation. Considering the legal provisions 
established in the Regulation (EC) No 1924/2006 
and relative acts, the evidence of ‘traditional use’ 
is insufficient to prove the substantiation of 
claims on botanicals and others miscellaneous 
bioactive substances. In this context it was 
generated in the EU market a controversial 
situation regarding medicinal products and food, 
usually FS. Some botanical or miscellaneous 
bioactive substances are used in both FS and 
medicines (e.g. glucosamine) [24]. As observed 
in this study, considering the rules of the 
Regulation (EC) No 1924/2006 it was expected 
that, in most, if not all, health claims on 
botanicals would be rejected. Regarding this 
situation the Commission, in agreement with the 
Member States, decided to reflect on this issue 
while the health claims on botanicals are put ‘on 
hold’ Regarding the resolution of this regulatory 
hiatus on botanicals, the two options put forward 
by the Commission are the following: (1) uphold 
the status quo, justifying the different treatment 
of botanicals between food and medicines; (2) 
consider that difference in treatment would not 
be justified. In this last position, botanicals would 
be considered a particular case in the food area, 
with eventually news rules recognising the 
importance of evidence of ‘traditional use’ 
[11,61]. Three Member States with great 
experience and tradition in FS containing 
botanicals (Italy, France and Belgium), supported 
by scientific expertises in this area joined forces 
in the BELFRIT project [62]. This project 
enhances the importance of the quality and 
safety aspects regarding botanicals used in FS 
and food in general. This debate on this issue is 
not completed yet. 
 
Several stakeholders, including the scientific 
community, have been questioning EFSA’s 
decisions and presenting their vision and/or 
suggestions on general aspects and regarding 
specific functions. The Group for the Respect of 
Ethics and Excellence in Science, GRES, 
published in 2012 a commentary on health 
claims assessment in the field of joint and 
cartilage [49]. In 2011, EFSA and its NDA Panel 
have carried out a written public consultation with 
stakeholders, on the draft document of the 
guidance on the scientific requirements for health 
claims related, among others, to joints health. A 
summary of the comments received by all 
interested parties (e.g. academia and research 
institutes, industry organizations and applicants 
for health claims) and of how the comments were 
addressed by the NDA Panel is part of EFSA's 
technical report published in 2012 [63].  
According to this report, the NDA Panel’s final 
version of the guidance document took into 
account the questions/comments received in that 
public consultation.  
 
Possible outcomes for Article 13.5 claims related 
to joint function could include a foodstuff that 
could decrease joint discomfort, e.g. stiffness 
and pain, improve joint mobility or changes in 
joint structure leading to maintenance of joint 
function [35]. In this regard, the NDA Panel 
scientific requirements for health claims related 
to joint function are aligned (both possible 
outcomes and outcomes measures) with the 
viewpoint of the GREES Panel [49]. The GREES 
Panel considers three potentially Article 13.5 
health claims on joints health: decrease in joint 
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discomfort, improvement in joint mobility and 
maintenance of structural joint integrity. 
According to the NDA Panel [39], decrease in 
joint discomfort and improvements in joint 
mobility are possible outcomes for the 
maintenance (i.e. reduced loss) of joint function; 
changes in joint structure, namely in joint space 
width, leading to the maintenance of joint 
function(s), can also be considered beneficial 
physiological effects. Structural changes in joint 
tissues, or changes in biochemical markers, 
namely of joint inflammation, proposed as 
mechanisms by which the FS/food constituent 
may exert the claimed effect on joint function, 
may also be considered a beneficial 
physiological effect, based on a case-by-case 
approach [39]. 
 
The EU Register does not include Article 14.1 
health claims for articular joints. For disease risk 
reduction claims the NDA Panel assumes that 
‘beneficial refers to whether the claimed effect 
relates to the reduction or beneficial alteration of 
a risk factor for the development (onset) of a 
human disease’ (not the reduction of the risk of 
disease) [31]. From the NDA Panel perspective, 
an increased rate of joint cartilage degeneration 
can be considered a risk factor for the onset of 
osteoarthritis/degenerative arthritis [39]. Studies 
measuring net cartilage loss could be used for 
the scientific substantiation of diseased risk 
reduction claims referring to osteoarthritis [39]. 
On the contrary, the NDA Panel does not 
consider changes in biomarkers of cartilage 
degeneration or of collagen turnover as risk 
factors for disease risk reduction claims relating 
to osteoarthritis [39].   
 
Scientific substantiation is the main aspect (and 
the greatest challenge) to take into account in 
health claims related to joint function. Human 
studies conducted in diseased populations are 
the main NDA Panel’s criterion for the non-
approval of the health claims on joints. According 
to EFSA [39]: ‘normal cells and tissues are 
genetically (gene expression) and functionally 
different from osteoarthritic cells and tissues and 
therefore may respond differently to interventions 
with exogenous substances’ and ‘the 
mechanisms involved in the onset and/or 
progression of osteoarthritis are largely unknown, 
so that it cannot be established that an 
intervention which has an effect on the 
progression of the disease (in patients with 
osteoarthritis), would also have an effect on its 
onset (subjects without the disease)’. On this 
subject the NDA Panel considered the findings of 
a study by Jordan et al. [64] entitled 
‘Methodological issues in clinical trials for 
prevention or risk reduction in osteoarthritis’, 
published in 2011. The NDA Panel viewpoint on 
the eligible study populations is clear [39]: the 
demonstration of the health claims on joints has 
to be established in human intervention studies 
performed in non-diseased (including high risk) 
population subgroups (e.g. Kell-Lawrence 
radiographic scores 0 or 1, obesity, knee varus 
or valgus malalignment). The EFSA NDA Panel 
guidance document recommends that the 
applicants provide information on the selection 
and characterisation of the study population in 
relation to the claimed effect and a rationale for 
extrapolation of the results to the target 
population for which the claim is made. 
   
Methodological issues in the design of clinical 
trials are (critical) specific challenges essential 
for obtaining reliable outcomes in human studies 
to provide a scientific basis for health claims 
related to joint function. Generally, EFSA 
scientific assessment of Article 13.1 claims 
included separate assessment of each 
relationship between the functional 
constituent/food and a claimed effect, and 
combining individual assessments, in order to 
obtain coherent opinions [34,37,40]. The NDA 
Panel evaluation of general function claims was 
carried out, in accordance with the general 
guidance document [31], with the available 
documents cited in references received from the 
Member States and from those provided by 
stakeholders, including data that are derived 
from the state-of-the-art peer-reviewed published 
literature, e.g. handbooks and monographs. For 
those Article 13.1 claims on joints there was no 
established consensus and the primary studies 
assessed were conducted in diseased 
populations.  
 
As referred previously, one general function 
claim on vitamin C related to cartilage formation 
was approved by EFSA. However is important to 
note that the NDA Panel decision relied on well 
established biochemical role of vitamin C in 
collagen structure and on Vitamin C deficiency 
symptoms on impaired collagen synthesis. 
Nowadays, the claim ‘Vitamin C contributes to 
normal collagen formation for the normal function 
of cartilage’ [46] is currently used on foodstuff. In 
order to bear this claim food supplement should 
be at least a source of vitamin C (i.e. 12 mg/100g 
or 100 mL) as per Annex to Regulation (EC) nº 
1924/2006 and Annex III to Regulation (UE) nº 
1169/2011.  
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Table 7. Overview on different national approaches for the use of some substances, other than vitamins and minerals, in the Member States  
of the UE* 
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 Evening Primrose oil 
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Aloe 
(Aloe vera (L.)) 
E √ E E C C L √ C  A C X C √ √ √ E √ √ √ √ √ √ C L/C √ √ C 
Ginkgo 
(Ginkgo bibola (L.)) 
E L E E C L √ X C  A X X L X C   L E √ √ √ √ √ √ L  X  X X C 
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√ Permitted for use in food supplements either under national law or internal guidelines 
L Permitted for use in food supplements - maximum level established 
C Permitted for use in food supplements under specific conditions (e.g. type of extract,  
E Permission may given on a case by case basis following evaluation, considering issues such as ingredient function 
A Not currently permitted. May be permitted following a pre-marketing authorisation 
X Not permitted for use in food supplements, or regarded as medicinal 
*adapted from European Advisory Services, 2007 [24]. 
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Well designed RCT studies are regarded as the 
most convincing proof for the scientific 
substantiation of health claims under Articles 
13.5 and 14.1.a. According to experts, in addition 
to being costly and difficult experimentally, those 
studies are not always feasible or available for 
nutritional studies [31]. The recent NDA Panel 
(draft) General scientific guidance on health 
claims applications states that pertinent human 
studies are central for health claim substantiation 
and intervention human studies at the top of the 
hierarchy that informs decisions on 
substantiation [52]. The reason for this NDA 
Panel approach resides on the need to provide 
evidence from the impact of introducing or 
replacing a single food/constituent in the whole 
diet on the claimed effect. This document also 
clarifies that pertinent human studies are 
intervention and observational human studies 
from which scientific conclusions can be drawn 
for the substantiation of a claim. Intervention and 
observational human studies can also provide 
evidence for a dose response relationship and 
for consistency of the effect/or the association 
across studies. For these applications it is 
important to consider that the applicant has the 
responsibility to provide the totality of the data 
available, namely supportive evidence from 
reviews, in vitro and animal studies. However, 
efficacy studies in animals and non-efficacy 
studies in humans (e.g. evidence for a 
mechanism which a food could exert the claimed 
effect) may be part of the totality of the evidence 
only if pertinent human studies showing an effect 
of the food/constituent are available [52]. The 
human trials must be conducted in non-diseased 
population subgroups (including high risk), have 
high methodological and statistical quality (e.g. 
addressing confounding factors and having 
sufficient statistical power) [31,32]. In the recent 
NDA Panel (draft) guidance document it is 
recognized that: (I) ‘the first-line therapy for 
patients with diet-related chronic diseases (e.g. 
obesity, type 2 diabetes, hypertension) is often 
dietary advice, and thus they could benefit the 
most from health claims made on foods’; (II) ‘in 
some cases, the relationship between a 
food/constituent and a function can be best 
measured by using disease outcomes’; (III) ‘with 
respect to the likelihood that the consumption of 
a food/constituent would effectively modify the 
risk of the disease, disease outcomes provide 
stronger evidence than risk factors for disease’ 
and ‘in some circumstances it may be easier to 
measure disease outcomes than risk factors for 
disease’ and considering ‘the likelihood that the 
consumption of a food / constituent would 
effectively modify the risk of the disease, disease 
outcomes provide stronger evidence than risk 
factors for disease’ [52]. Consequently, among 
others, the Panel also considers that ‘studies 
conducted in subjects with a disease may be 
used to substantiate function claims for the 
general population or subgroups thereof (without 
the disease) as long as the effect of the 
food/constituent on the body function which is 
named in the claim is expected to occur in 
subjects without the disease and a rationale is 
given for such expectations’ [52]. On the study 
population, the GREES Panel suggested 
technical information to consider in future 
studies, along with EFSA’s guidance 
recommendations [39,49]. The EFSA NDA Panel 
(draft) General scientific guidance on health 
claims applications is more aligned with the 
GREES Panel approach. 
 
Not all human intervention studies are accepted 
by EFSA as evidence. In the positive opinion 
related to polyphenols on olive oil and protection 
of LDL particles from oxidative damage, the NDA 
Panel took into account a well conducted and 
powered study (a multicentre, randomized, 
cross-over, controlled human trial in 200 
volunteers for 3 weeks) and two smaller-scale 
studies (a randomized, cross-over, controlled 
human trial in 36 volunteers for 3 weeks and a 
controlled, double-bind, cross-over, randomized, 
human trial in 30 and 12 healthy male volunteers 
for 3 weeks and 4 days, respectively); supported 
by one short-term  (controlled, double-bind, 
cross-over, randomized, human trial in 12 
healthy male volunteers for  4 days), and one 
acute (cross-over study design in 12 healthy 
male volunteers) and by supportive markers of 
LDL peroxidation [50]. Two other human trials (a 
randomized, single-blind, cross-over trial in 25 
healthy male and female smokers for 3 weeks 
and a randomized, sequential cross-over, acute 
study in 21 hypercholesterolaemic volunteers) 
were not considered for the substantiation of the 
claimed effect [50]. In this scenario it is worth 
remembering that in time of financial crisis, 
conducting human studies able to meet those 
requirements is a huge financial effort, for many 
difficult to undertake. Finally, as for clinical trials 
on medicinal products for human use [65], the 
creation of harmonized scientifically robust 
criteria and guidance for the conduct of 
nutritional intervention studies in humans, more 
in line with the multiple effects of nutrition could 
have a huge impact on health claims on food in 
general [31,66]. In this regard, the recent EFSA 
NDA Panel (draft) General scientific guidance on 
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health claims applications can represent an 
important shift regarding the evaluation of future 
health claims on joints [52]. 
 
4. CONCLUSION 
 
FS in the EU market contain nutrients and other 
substances, namely amino acids, enzymes, pre- 
and probiotics, essential fatty acids, botanicals 
and botanical extracts, and miscellaneous 
bioactive substances. The key provisions of the 
FDS include a positive list of vitamins and 
minerals and of their specific forms and specific 
rules regarding labeling. Specific provisions for 
the use of other substances are subject to 
national law and/or internal guidelines, with 
negative and positive lists and considering 
specific conditions of use. Furthermore, a 
significant proportion of the EU market in some 
of the miscellaneous bioactive substances and 
botanicals are composed by products registered 
in different member States, both as medicines 
and as food. These borderline cases regarding 
botanicals and other bioactive substances raised 
up a great controversial in the EU, namely 
regarding the assessment of health claims on 
those products. 
 
In the EU market FS cannot bear such health 
claims unless the claims have been authorised. 
But, since July 2007, with the entry into force of 
Regulation (EC) nº 1924/2006 only health claims 
that are supported by a sufficient body of 
scientific evidence able to substantiate the 
relationship between the consumption of the 
foodstuff and the claimed effect are admitted. 
However, in general, the implementation of this 
Regulation has been very criticized, namely 
regarding the scientific assessment of health 
claims on other substances, namely botanicals 
and various miscellaneous bioactive substances.  
 
EFSA assessment favours effects improving 
joints health of the consumer, as described in 
Regulation (EC) nº 1924/2006.The 77 functional 
health claims on joints health included in the EU 
Register have not been authorised.  According to 
EFSA assessments, applicants have provided 
very limited or no evidence, and no cause and 
effect have been positively assessed in each 
case. The main reason for EFSA non-approval is 
that the evidence submitted to EFSA for 
substantiation did not establish that data from 
diseased groups can be extrapolated to the 
general population that is the target for these 
claims. However, it is relevant to note that 
EFSA’s criteria I (the target ingredient is defined 
and characterized), and II (the claimed effect is a 
beneficial physiological effect), have been 
positively assessed in 75 claims. 
 
Some of the 77 health claims on joints analysed 
in this work were made on botanicals and 
miscellaneous bioactive substances. Depending 
on the intended use of the product, these same 
ingredients can also be used in medicines.  Many 
of these medicinal products are regulated under 
the Traditional Herbal Medicine Products 
Directive, through a simplified traditional use 
registration that recognizes, under certain strict 
conditions, the importance of the evidence of 
‘traditional use’, regarding both safety and 
efficacy of these products. On the contrary, 
under Regulation (CE) nº 1924/2006, the 
evidence of ‘traditional use’ is not sufficient to 
prove the substantiation of claims on botanicals 
and others miscellaneous bioactive substances. 
Regarding the resolution of this regulatory hiatus 
on botanicals, some options are currently in 
discussion: (1) upholding the status quo, 
justifying the different treatment of botanicals 
between food and medicines; (2) accepting that 
difference in treatment would not be justified with 
different rules recognising the importance of 
evidence of ‘traditional use’. The importance of 
the quality and safety aspects regarding 
botanicals used in FS and food in general has 
been pointed out by the BELFRIT project as 
crucial. In our point of view, this debate could 
provide new insights regarding the 
implementation of Regulation (EC) nº 1924/2006. 
 
It is important to learn from the experience of this 
scientific assessment by the EFSA in order to 
achieve in having FS with authorized health 
claims related to joint health and to ensure 
confidence in claims on FS, including FS 
containing botanicals ingredients. Thus, research 
strategy and tools should be oriented to meet the 
legal requirements in force and the EFSA 
scientific guidelines recommendations. However, 
criteria and more detailed guidance documents 
provided by EFSA with a collaborative 
involvement of stakeholders, including scientists 
from academia and research institutes, 
especially addressing methodological issues on 
human trials in general and related to the joints 
function, would benefit all future applications and 
scientific research in this field. Specific legal 
issues regarding other substances, namely 
botanical ingredients and botanical preparations, 
should also be taken into account in future FS 
health claims on articular joint. On legal subjects, 
it would be advisable for the European 
  
 
 
Bettencourt-Câmara et al.; EJNFS, 6(1): 12-35, 2016; Article no.EJNFS.2016.003 
 
 
 
30 
 
Commission and Member States to undertake 
efforts to improve the existing regulatory 
framework, namely with regard to FS. 
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